ANTI-EGFR ANTIBODY POLYTHERAPY

MA40968AUndetermined Publication Date: 2017-10-04FORMATION BIOLOGICS

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MA40968
Authority / Receiving Office: MA · MA
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2014-10-31
Filing Date: 2015-10-30
Publication Date: 2017-10-04

Application Information

Patent Timeline

31 Oct 2014

Priority

30 Oct 2015

Application

MA40968

04 Oct 2017

Publication

MA40968A

IPC: A61K39/395; A61P35/00; C07K16/28

CPC: A61K39/395; C07K16/2863; A61K47/6817; A61K47/6849; A61P35/00; A61K47/68033; A61K47/00

Inventors: TIKHOMIROV Ilia Alexandre

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Anti-EGFR antibodies can be combined to enhance their anticancer effect. In the present invention, at least one of two naked antibodies in a combination is provided as an antibody drug conjugate (ADC) in which the antibody is coupled to a cytotoxin. Both antibodies can also be provided as ADCs. The result is enhanced activity, with the enhancement being synergistic in many such antibody pairs.

Need to check novelty before this filing date? Find Prior Art